| Recruiting | A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metast NCT07264816 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 |
| Enrolling By Invitation | Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum- NCT07285434 | Biogenea Pharmaceuticals Ltd. | EARLY_Phase 1 |
| Not Yet Recruiting | Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy a NCT07383116 | Shanghai Huaota Biopharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or NCT07178795 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combin NCT07005102 | AbbVie | Phase 2 / Phase 3 |
| Recruiting | A Study of JS207 (PD-1/VEGF Bispecific Antibody) in Combination With Chemotherapy in Advanced Non-small Cell L NCT06868836 | Shanghai Junshi Bioscience Co., Ltd. | Phase 2 |
| Not Yet Recruiting | A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in NCT06847334 | Shanghai Henlius Biotech | Phase 3 |
| Recruiting | A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic NCT06939595 | Celltrion | Phase 3 |
| Recruiting | A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Bios NCT06687369 | mAbxience Research S.L. | Phase 3 |
| Not Yet Recruiting | A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in t NCT06724263 | Tasly Biopharmaceuticals Co., Ltd. | Phase 2 |
| Recruiting | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metas NCT06627647 | AstraZeneca | Phase 3 |
| Terminated | Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in NCT06643117 | Formycon AG | Phase 3 |
| Recruiting | RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platin NCT06491862 | AstraZeneca | — |
| Recruiting | A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung NCT06417008 | Hansoh BioMedical R&D Company | Phase 2 / Phase 3 |
| Not Yet Recruiting | A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NS NCT06335355 | Shanghai Shengdi Pharmaceutical Co., Ltd | Phase 2 / Phase 3 |
| Recruiting | Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Trea NCT05841472 | CrystalGenomics, Inc. | Phase 2 |
| Not Yet Recruiting | Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation NCT05962021 | Peking University People's Hospital | Phase 2 |
| Terminated | The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Comb NCT05849246 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 |
| Unknown | Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatme NCT06334757 | Henan Cancer Hospital | Phase 2 |
| Active Not Recruiting | Phase III Study of AK112 for NSCLC Patients NCT06396065 | Summit Therapeutics | Phase 3 |
| Terminated | A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell L NCT05317078 | Amgen | Phase 1 |
| Completed | Safety of Effivia®, a Bevacizumab Biosimilar NCT06313268 | Laboratorios Liomont | — |
| Active Not Recruiting | Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations NCT05258279 | Juntendo University | Phase 2 |
| Unknown | A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant No NCT05338619 | Sung Yong Lee | Phase 2 |
| Terminated | Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High NCT05245071 | Sanofi | Phase 2 |
| Unknown | Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC NCT05394233 | Sichuan Cancer Hospital and Research Institute | Phase 2 |
| Recruiting | A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers NCT05403554 | Light Chain Bioscience - Novimmune SA | Phase 1 |
| Active Not Recruiting | Phase 3 Clinical Study of AK112 for NSCLC Patients NCT05184712 | Akeso | Phase 3 |
| Active Not Recruiting | Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC NCT04958811 | Georgetown University | Phase 2 |
| Completed | Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent The NCT04795245 | Boehringer Ingelheim | — |
| Terminated | A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC. NCT04619433 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Terminated | NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial NCT04698681 | Calithera Biosciences, Inc | — |
| Completed | Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamo NCT04750824 | Boehringer Ingelheim | — |
| Terminated | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) NCT04504916 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Terminated | KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, NCT04265534 | Calithera Biosciences, Inc | Phase 2 |
| Unknown | Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell NCT04453423 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Unknown | Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901 NCT04396457 | National Hospital Organization Nagoya Medical Center | Phase 2 |
| Completed | The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) M NCT04206787 | Boehringer Ingelheim | — |
| Completed | A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer NCT05318443 | Shanghai Institute Of Biological Products | Phase 3 |
| Terminated | Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesotheli NCT04173338 | Augusta University | Phase 1 |
| Unknown | Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC NCT04211090 | Sun Yat-sen University | Phase 2 |
| Completed | The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epide NCT04179890 | Boehringer Ingelheim | — |
| Recruiting | Study of Crizotinib for ROS1 and MET Activated Lung Cancer NCT04084717 | University Health Network, Toronto | Phase 2 |
| Unknown | Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC NCT04063449 | Dong Wang | N/A |
| Completed | Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non- NCT03802240 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 |
| Unknown | Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non NCT03992885 | Tianjin Medical University Cancer Institute and Hospital | Phase 3 |
| Completed | Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer NCT04012619 | Sichuan University | Phase 1 |
| Withdrawn | Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous NCT03319316 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Unknown | Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin NCT03671538 | Lingyu Luo | N/A |
| Unknown | Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study NCT03646968 | Yongchang Zhang | Phase 2 |
| Unknown | Phase I Study of the Combination of Anlotinib With Gefitinib NCT03602027 | Second Affiliated Hospital of Nanchang University | N/A |
| Completed | A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cel NCT03468426 | Boehringer Ingelheim | Phase 1 |
| Unknown | Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel NCT03566576 | Fujian Cancer Hospital | N/A |
| Completed | A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Canc NCT03329911 | Bio-Thera Solutions | Phase 3 |
| Unknown | A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone NCT03127319 | Affiliated Hospital of Hebei University | Phase 2 |
| Unknown | Apatinib in Advanced Non-squamous，NSCLC NCT03376191 | Jian Fang | — |
| Completed | Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First- NCT03169335 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors NCT02835833 | University of Alabama at Birmingham | Phase 1 |
| Unknown | Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutat NCT02633189 | National Cancer Institute, Naples | Phase 3 |
| Completed | Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-S NCT01951482 | Sun Yat-sen University | Phase 3 |
| Completed | Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherap NCT02264990 | AbbVie | Phase 3 |
| Withdrawn | A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients W NCT01702714 | Hoffmann-La Roche | Phase 1 |
| Completed | A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small NCT02008227 | Hoffmann-La Roche | Phase 3 |
| Completed | ASPET Study: An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced Non-Small C NCT01723878 | Hoffmann-La Roche | — |
| Completed | A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian C NCT01995188 | Genentech, Inc. | Phase 1 |
| Completed | A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small NCT01887886 | Hoffmann-La Roche | Phase 3 |
| Completed | An Observational Study of Avastin (Bevacizumab) in Elderly Patients With Non-Squamous Non-Small Cell Lung Canc NCT01893268 | Hoffmann-La Roche | — |
| Completed | Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lun NCT01829113 | SCRI Development Innovations, LLC | Phase 2 |
| Completed | An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcino NCT01836133 | Hoffmann-La Roche | — |
| Completed | Paclitaxel-bevacizumab in Advanced Lung Cancer NCT01763671 | Intergroupe Francophone de Cancerologie Thoracique | Phase 3 |
| Terminated | A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemot NCT01990261 | Hoffmann-La Roche | — |
| Completed | AVAdeno Study: An Observational Study of First-Line Avastin (Bevacizumab) in Patients With Adenocarcinoma of t NCT01827852 | Hoffmann-La Roche | — |
| Completed | An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive N NCT01790217 | Hoffmann-La Roche | — |
| Completed | PEPITA Study: An Observational Study of Tarceva (Erlotinib) in Second Line in Patients With Locally Advanced o NCT01659970 | Hoffmann-La Roche | — |
| Completed | A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcino NCT01609543 | Hoffmann-La Roche | Phase 4 |
| Completed | A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With NCT01496742 | Genentech, Inc. | Phase 2 |
| Completed | A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With S NCT01519804 | Genentech, Inc. | Phase 2 |
| Completed | A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cance NCT01372384 | Hoffmann-La Roche | Phase 2 |
| Completed | A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Po NCT01456325 | Genentech, Inc. | Phase 3 |
| Completed | An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung NCT01512420 | Hoffmann-La Roche | — |
| Completed | A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advan NCT01328951 | Hoffmann-La Roche | Phase 3 |
| Completed | An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Me NCT01664533 | Hoffmann-La Roche | — |
| Completed | A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamo NCT01351415 | Hoffmann-La Roche | Phase 3 |
| Completed | An Observational Study on Patients With Non-Squamous NSCLC Who Reached A Long PFS After Avastin (Bevacizumab)- NCT01343914 | Hoffmann-La Roche | — |
| Completed | Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizu NCT01366131 | Genentech, Inc. | Phase 2 |
| Completed | A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participant NCT01174563 | Hoffmann-La Roche | Phase 2 |
| Completed | An Observational Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer NCT01535729 | Hoffmann-La Roche | — |
| Completed | An Observational Study of Lung Cancer Related Symptoms and Disease Control Rate in Patients With Non-Small Cel NCT01358942 | Hoffmann-La Roche | — |
| Completed | A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbourin NCT01310036 | Hoffmann-La Roche | Phase 2 |
| Completed | A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epide NCT01260181 | Hoffmann-La Roche | Phase 2 |
| Completed | A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRI NCT01378962 | Hoffmann-La Roche | Phase 2 |
| Completed | A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastat NCT01250119 | Hoffmann-La Roche | Phase 2 |
| Terminated | Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung NCT01244191 | Daiichi Sankyo | Phase 3 |
| Completed | A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or R NCT01185847 | Hoffmann-La Roche | Phase 2 |
| Completed | A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced NCT01204697 | Hoffmann-La Roche | Phase 2 |
| Completed | An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic o NCT01333007 | Hoffmann-La Roche | — |
| Completed | Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer NCT01160601 | Peregrine Pharmaceuticals | Phase 2 |
| Completed | An Observational Study of Tarceva (Erlotinib) in Routine Practice For First Line Maintenance Therapy in Patien NCT01194050 | Hoffmann-La Roche | — |
| Completed | An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer NCT01488331 | Hoffmann-La Roche | — |
| Completed | A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treat NCT01077713 | Hoffmann-La Roche | Phase 2 |
| Terminated | Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) NCT01057212 | Providence Health & Services | Phase 2 |
| Completed | An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer NCT01070927 | Hoffmann-La Roche | Phase 2 |
| Completed | A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel NCT00974584 | Genentech, Inc. | Phase 1 |
| Completed | Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-ang NCT00988936 | Siemens Molecular Imaging | Phase 2 |
| Completed | Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung NCT00976456 | PD Dr. med. Wolfgang Schuette | Phase 3 |
| Completed | AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avast NCT00961415 | Hoffmann-La Roche | Phase 3 |
| Completed | A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment i NCT00883779 | Hoffmann-La Roche | Phase 3 |
| Completed | A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lu NCT01066884 | Hoffmann-La Roche | Phase 4 |
| Completed | A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Adva NCT00776698 | Hoffmann-La Roche | Phase 1 |
| Completed | A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vin NCT00773188 | Hoffmann-La Roche | Phase 1 |
| Terminated | A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patient NCT00760929 | Hoffmann-La Roche | Phase 2 |
| Completed | A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash NCT00642473 | Hoffmann-La Roche | Phase 2 |
| Completed | Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) NCT02596958 | Hoffmann-La Roche | — |
| Completed | A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung C NCT00518011 | Hoffmann-La Roche | Phase 2 |
| Terminated | A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurr NCT00642824 | Hoffmann-La Roche | Phase 2 |
| Completed | A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advance NCT00451906 | Hoffmann-La Roche | Phase 4 |
| Completed | A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer NCT00152477 | UCB Pharma | Phase 2 |
| Completed | A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC) NCT02774278 | Hoffmann-La Roche | Phase 2 |
| Completed | A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) NCT00806923 | Hoffmann-La Roche | Phase 3 |
| No Longer Available | Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC Aft NCT02475382 | Bristol-Myers Squibb | — |